BlackRock Inc. cut its holdings in shares of Uniqure NV (NASDAQ:QURE) by 2.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 468,249 shares of the biotechnology company’s stock after selling 12,857 shares during the period. BlackRock Inc.’s holdings in Uniqure were worth $13,495,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the business. Federated Investors Inc. PA lifted its position in Uniqure by 43.5% during the 3rd quarter. Federated Investors Inc. PA now owns 1,565,600 shares of the biotechnology company’s stock worth $56,972,000 after buying an additional 474,320 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Uniqure by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 101,992 shares of the biotechnology company’s stock valued at $3,712,000 after purchasing an additional 3,992 shares during the period. Vanguard Group Inc raised its holdings in shares of Uniqure by 4.1% in the 3rd quarter. Vanguard Group Inc now owns 101,992 shares of the biotechnology company’s stock valued at $3,712,000 after purchasing an additional 3,992 shares during the period. Alps Advisors Inc. bought a new stake in shares of Uniqure in the 4th quarter valued at about $2,460,000. Finally, Allianz Asset Management GmbH raised its holdings in shares of Uniqure by 9.4% in the 3rd quarter. Allianz Asset Management GmbH now owns 54,332 shares of the biotechnology company’s stock valued at $1,977,000 after purchasing an additional 4,679 shares during the period. 60.52% of the stock is currently owned by hedge funds and other institutional investors.
In other Uniqure news, CEO Matthew C. Kapusta sold 19,085 shares of the stock in a transaction that occurred on Monday, January 28th. The shares were sold at an average price of $31.42, for a total transaction of $599,650.70. Following the transaction, the chief executive officer now owns 490,028 shares in the company, valued at approximately $15,396,679.76. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Christian Klemt sold 1,546 shares of the stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total transaction of $88,400.28. Following the transaction, the insider now owns 54,539 shares in the company, valued at approximately $3,118,540.02. The disclosure for this sale can be found here. Over the last three months, insiders sold 107,697 shares of company stock worth $5,821,088. Insiders own 1.56% of the company’s stock.
A number of brokerages have recently issued reports on QURE. BidaskClub raised shares of Uniqure from a “strong sell” rating to a “sell” rating in a report on Thursday, January 31st. Chardan Capital upped their target price on shares of Uniqure from $70.00 to $100.00 and gave the company a “buy” rating in a report on Monday, March 4th. Zacks Investment Research raised shares of Uniqure from a “sell” rating to a “hold” rating in a report on Thursday, January 17th. Piper Jaffray Companies began coverage on shares of Uniqure in a report on Friday, April 12th. They issued an “overweight” rating and a $80.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Uniqure in a report on Tuesday, February 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $74.73.
Uniqure stock opened at $53.70 on Friday. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of -22.95 and a beta of 1.08. The company has a current ratio of 11.85, a quick ratio of 11.85 and a debt-to-equity ratio of 0.20. Uniqure NV has a twelve month low of $21.98 and a twelve month high of $69.60.
Uniqure (NASDAQ:QURE) last released its quarterly earnings results on Thursday, February 28th. The biotechnology company reported ($0.59) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.67) by $0.08. Uniqure had a negative net margin of 738.25% and a negative return on equity of 47.73%. As a group, equities analysts forecast that Uniqure NV will post -3 earnings per share for the current fiscal year.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Further Reading: Quiet Period Expirations
Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Uniqure NV (NASDAQ:QURE).
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.